NYSE:LLY 15 January 2026 - 24 January 2026

Eli Lilly and Company shares nudged up Tuesday following news of a U.S. FDA Breakthrough Therapy designation for its experimental ovarian-cancer drug. The stock traded around $1,040.38, up roughly 0.2%, after starting the session at $1,020 and dipping to a low of $1,019.66. Meanwhile, the SPDR S&P 500 ETF slipped about 1%.

Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication.

Eli Lilly shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.”

Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill.

Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97.

Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns raised by FDA scientists.